The global ADME toxicology testing market size reached US$ 8.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 17.4 Billion by 2028, exhibiting a growth rate (CAGR) of 13.6% during 2022-2028.

Absorption, distribution, metabolism and excretion (ADME) toxicology testing is conducted at an early phase of the drug development process to determine the safety, uptake, elimination, effectiveness and metabolic behavior of a parent compound or drug in living organisms. It is generally carried out by researchers in cell-based and in vitro assays using software solutions, devices, detectors, etc. to identify active compounds, genetic interactions and other biomolecular interactions. It helps in understanding the safety and toxicity of a drug candidate before progressing it into a late stage preclinical and clinical studies, thereby saving cost, drug discovery time and test complications.

The growing prevalence of diseases is increasing the requirement of novels drugs and biological products. This represents one of the key factors escalating the adoption of ADME toxicology testing to prevent the failure of candidate drugs at late-stage clinical trials.111 It also helps researchers to determine the viability of these drugs necessary for regulatory approval. Additionally, one of the key trends witnessed in the market is the introduction of several guidance documents by the Food and Drug Administration (FDA) to provide instruction about ADME properties when evaluating the safety and efficacy of a drug candidate. Apart from this, the introduction of software that can calculate ADME automatically is gaining traction over conventional in vitro assays and in vivo experiments. Furthermore, due to the mass outbreak of the coronavirus disease (COVID-19) and a significant lack of an effective vaccine or treatment, ADME toxicology testing is being utilized to calculate the efficacy of existing drugs as an alternative treatment, which is also augmenting the market growth.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global ADME toxicology testing market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on technology, product type, method and application.

Breakup by Technology:

Cell Culture
High Throughput Screening
Molecular Imaging
OMICS Technology

Breakup by Product Type:

Software Solutions
Assay Systems

Breakup by Method:


Breakup by Application:

Systemic Toxicity
Renal Toxicity

Breakup by Region:

North America
United States
South Korea
United Kingdom
Latin America
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Beckman Coulter Inc. (Danaher Corporation), Bioivt LLC, Bio-Rad Laboratories Inc., Charles River Laboratories International Inc., Cyprotex Plc (Evotec AG), Molecular Discovery Ltd., Perkinelmer Inc., Promega Corporation and Thermo Fisher Scientific Inc.

Key questions answered in this report:
How has the global ADME toxicology testing market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global ADME toxicology testing market?
What are the key regional markets?
What is the breakup of the market based on the technology?
What is the breakup of the market based on the product type?
What is the breakup of the market based on the method?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global ADME toxicology testing market and who are the key players?
What is the degree of competition in the industry?